Loading...

Oncodesign Société Anonyme

ENXTPA:ALONC
Snowflake Description

Adequate balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ALONC
ENXTPA
€50M
Market Cap
  1. Home
  2. FR
  3. Pharmaceuticals & Biotech
Company description

Oncodesign Société Anonyme, a biotechnology company, conducts research and development work on new therapeutic and diagnostic tools along with pharmaceutical firms, biotech companies, public research institutions, and investment groups. The last earnings update was 40 days ago. More info.


Add to Portfolio Compare Print
ALONC Share Price and Events
7 Day Returns
4.5%
ENXTPA:ALONC
1.5%
FR Biotechs
1.6%
FR Market
1 Year Returns
-30.7%
ENXTPA:ALONC
-35.4%
FR Biotechs
-4.4%
FR Market
ALONC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Oncodesign Société Anonyme (ALONC) 4.5% -1.1% 1.9% -30.7% -62.6% 11.1%
FR Biotechs 1.5% -4.7% 0.2% -35.4% -52.5% -35.5%
FR Market 1.6% -3.8% 3.8% -4.4% 29.3% 26.7%
1 Year Return vs Industry and Market
  • ALONC outperformed the Biotechs industry which returned -35.4% over the past year.
  • ALONC underperformed the Market in France which returned -4.4% over the past year.
Price Volatility
ALONC
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Oncodesign Société Anonyme undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Oncodesign Société Anonyme to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Oncodesign Société Anonyme.

ENXTPA:ALONC Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10.2%
Perpetual Growth Rate 10-Year FR Government Bond Rate 0.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for ENXTPA:ALONC
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year FR Govt Bond Rate 0.7%
Equity Risk Premium S&P Global 6.7%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.38
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.381 (1 + (1- 33%) (26.54%))
1.42
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.42
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.73% + (1.42 * 6.65%)
10.18%

Discounted Cash Flow Calculation for ENXTPA:ALONC using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Oncodesign Société Anonyme is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

ENXTPA:ALONC DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 10.18%)
2019 -0.90 Analyst x2 -0.81
2020 2.20 Analyst x2 1.81
2021 5.00 Analyst x1 3.74
2022 7.74 Est @ 54.7% 5.25
2023 10.71 Est @ 38.51% 6.60
2024 13.63 Est @ 27.18% 7.62
2025 16.25 Est @ 19.24% 8.24
2026 18.47 Est @ 13.69% 8.51
2027 20.28 Est @ 9.8% 8.48
2028 21.72 Est @ 7.08% 8.24
Present value of next 10 years cash flows €57.67
ENXTPA:ALONC DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= €21.72 × (1 + 0.73%) ÷ (10.18% – 0.73%)
€231.67
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €231.67 ÷ (1 + 10.18%)10
€87.90
ENXTPA:ALONC Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €57.67 + €87.90
€145.57
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €145.57 / 6.80
€21.4
ENXTPA:ALONC Discount to Share Price
Calculation Result
Value per share (EUR) From above. €21.40
Current discount Discount to share price of €7.42
= -1 x (€7.42 - €21.40) / €21.40
65.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Oncodesign Société Anonyme is available for.
Intrinsic value
>50%
Share price is €7.42 vs Future cash flow value of €21.4
Current Discount Checks
For Oncodesign Société Anonyme to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Oncodesign Société Anonyme's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Oncodesign Société Anonyme's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Oncodesign Société Anonyme's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Oncodesign Société Anonyme's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ENXTPA:ALONC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €-0.46
ENXTPA:ALONC Share Price ** ENXTPA (2019-05-21) in EUR €7.42
France Biotechs Industry PE Ratio Median Figure of 8 Publicly-Listed Biotechs Companies 18.29x
France Market PE Ratio Median Figure of 419 Publicly-Listed Companies 17.64x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Oncodesign Société Anonyme.

ENXTPA:ALONC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:ALONC Share Price ÷ EPS (both in EUR)

= 7.42 ÷ -0.46

-16.13x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Oncodesign Société Anonyme is loss making, we can't compare its value to the FR Biotechs industry average.
  • Oncodesign Société Anonyme is loss making, we can't compare the value of its earnings to the France market.
Price based on expected Growth
Does Oncodesign Société Anonyme's expected growth come at a high price?
Raw Data
ENXTPA:ALONC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -16.13x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
90.4%per year
France Biotechs Industry PEG Ratio Median Figure of 7 Publicly-Listed Biotechs Companies 0.33x
France Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.45x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Oncodesign Société Anonyme, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Oncodesign Société Anonyme's assets?
Raw Data
ENXTPA:ALONC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €0.68
ENXTPA:ALONC Share Price * ENXTPA (2019-05-21) in EUR €7.42
France Biotechs Industry PB Ratio Median Figure of 33 Publicly-Listed Biotechs Companies 2.26x
France Market PB Ratio Median Figure of 619 Publicly-Listed Companies 1.45x
ENXTPA:ALONC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:ALONC Share Price ÷ Book Value per Share (both in EUR)

= 7.42 ÷ 0.68

10.94x

* Primary Listing of Oncodesign Société Anonyme.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Oncodesign Société Anonyme is overvalued based on assets compared to the FR Biotechs industry average.
X
Value checks
We assess Oncodesign Société Anonyme's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Oncodesign Société Anonyme has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Oncodesign Société Anonyme expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
90.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Oncodesign Société Anonyme expected to grow at an attractive rate?
  • Oncodesign Société Anonyme's earnings growth is expected to exceed the low risk savings rate of 0.7%.
Growth vs Market Checks
  • Oncodesign Société Anonyme's earnings growth is expected to exceed the France market average.
  • Oncodesign Société Anonyme's revenue growth is expected to exceed the France market average.
Annual Growth Rates Comparison
Raw Data
ENXTPA:ALONC Future Growth Rates Data Sources
Data Point Source Value (per year)
ENXTPA:ALONC Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 90.4%
ENXTPA:ALONC Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 12%
France Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 32.8%
France Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 39.7%
France Market Earnings Growth Rate Market Cap Weighted Average 13.2%
France Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ENXTPA:ALONC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ENXTPA:ALONC Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 0 0
2020-12-31 35 5 4 2
2019-12-31 29 2 1 1
ENXTPA:ALONC Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 28 0 -3
2018-09-30 25 -4 -5
2018-06-30 29 -8 -7
2018-03-31 27 -7 -6
2017-12-31 22 -6 -5
2017-09-30 23 -2 -2
2017-06-30 18 3 1
2017-03-31 15 2 1
2016-12-31 15 1 1
2016-09-30 14 0
2016-06-30 14 -1 0
2016-03-31 15 -1 1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Oncodesign Société Anonyme's earnings are expected to grow significantly at over 20% yearly.
  • Oncodesign Société Anonyme's revenue is expected to grow by 12% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ENXTPA:ALONC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Oncodesign Société Anonyme Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTPA:ALONC Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 -0.03 -0.03 -0.03 1.00
2020-12-31 0.68 1.01 0.32 3.00
2019-12-31 0.09 0.26 -0.09 2.00
ENXTPA:ALONC Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 -0.46
2018-09-30 -0.71
2018-06-30 -0.96
2018-03-31 -0.85
2017-12-31 -0.73
2017-09-30 -0.32
2017-06-30 0.08
2017-03-31 0.08
2016-12-31 0.09
2016-09-30 0.03
2016-06-30 -0.04
2016-03-31 0.08

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Oncodesign Société Anonyme is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Oncodesign Société Anonyme's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the France market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the France market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Oncodesign Société Anonyme has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Oncodesign Société Anonyme performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Oncodesign Société Anonyme's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Oncodesign Société Anonyme does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Oncodesign Société Anonyme's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Oncodesign Société Anonyme's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Oncodesign Société Anonyme's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Oncodesign Société Anonyme Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTPA:ALONC Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 28.39 -3.15 15.99
2018-09-30 25.22 -4.86 15.54
2018-06-30 28.88 -6.57 15.10
2018-03-31 27.28 -5.78 13.98
2017-12-31 22.26 -5.00 12.87
2017-09-30 22.79 -2.23 11.26
2017-06-30 18.08 0.54 9.65
2017-03-31 15.38 0.59 8.38
2016-12-31 14.51 0.64 7.11
2016-09-30 14.47 0.20 6.77
2016-06-30 14.42 -0.24 6.42
2016-03-31 14.58 0.52 6.13
2015-12-31 14.74 1.27 5.83
2015-09-30 12.58 -0.07 5.29
2015-06-30 10.41 -1.42 4.76
2015-03-31 8.95 -1.86 4.30
2014-12-31 7.48 -2.30 3.85
2014-09-30 7.68 -1.43 3.71
2014-06-30 7.89 -0.56 3.57
2014-03-31 7.76 -0.76 3.52
2013-12-31 7.64 -0.96 3.48
2012-12-31 7.53 0.79 3.51

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Oncodesign Société Anonyme has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Oncodesign Société Anonyme has efficiently used its assets last year compared to the FR Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Oncodesign Société Anonyme improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Oncodesign Société Anonyme's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Oncodesign Société Anonyme has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Oncodesign Société Anonyme's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Oncodesign Société Anonyme's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Oncodesign Société Anonyme is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Oncodesign Société Anonyme's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Oncodesign Société Anonyme's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Oncodesign Société Anonyme Company Filings, last reported 4 months ago.

ENXTPA:ALONC Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 6.70 13.39 10.09
2018-09-30 6.70 13.39 10.09
2018-06-30 6.16 13.09 9.78
2018-03-31 6.16 13.09 9.78
2017-12-31 9.47 13.31 11.54
2017-09-30 9.47 13.31 11.54
2017-06-30 12.35 1.26 10.18
2017-03-31 12.35 1.26 10.18
2016-12-31 14.28 1.54 9.89
2016-09-30 14.28 1.54 9.89
2016-06-30 11.50 0.71 9.17
2016-03-31 11.50 0.71 9.17
2015-12-31 13.38 1.05 9.25
2015-09-30 13.38 1.05 9.25
2015-06-30 10.68 0.13 9.48
2015-03-31 10.68 0.13 9.48
2014-12-31 10.77 0.20 10.23
2014-09-30 10.77 0.20 10.23
2014-06-30 11.85 0.18 10.70
2014-03-31 11.85 0.18 10.70
2013-12-31 1.72 0.25 1.10
2012-12-31 2.52 0.13 1.81
  • Oncodesign Société Anonyme's level of debt (200%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (13.4% vs 200% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Oncodesign Société Anonyme has sufficient cash runway for more than 3 years based on current free cash flow.
  • Oncodesign Société Anonyme has sufficient cash runway for 2.5 years if free cash flow continues to grow at historical rates of 60.8% each year.
X
Financial health checks
We assess Oncodesign Société Anonyme's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Oncodesign Société Anonyme has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Oncodesign Société Anonyme's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Oncodesign Société Anonyme dividends. Estimated to be 0% next year.
If you bought €2,000 of Oncodesign Société Anonyme shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Oncodesign Société Anonyme's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Oncodesign Société Anonyme's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ENXTPA:ALONC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.8%
France Market Average Dividend Yield Market Cap Weighted Average of 323 Stocks 3.1%
France Minimum Threshold Dividend Yield 10th Percentile 1%
France Bottom 25% Dividend Yield 25th Percentile 1.6%
France Top 25% Dividend Yield 75th Percentile 4.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ENXTPA:ALONC Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Oncodesign Société Anonyme has not reported any payouts.
  • Unable to verify if Oncodesign Société Anonyme's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Oncodesign Société Anonyme's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Oncodesign Société Anonyme has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Oncodesign Société Anonyme's dividends in 3 years as they are not expected to pay a notable one for France.
X
Income/ dividend checks
We assess Oncodesign Société Anonyme's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Oncodesign Société Anonyme afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Oncodesign Société Anonyme has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Oncodesign Société Anonyme's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Philippe Genne
COMPENSATION €204,420
TENURE AS CEO 9 years
CEO Bio

Dr. Philippe Genne, Ph.D., Founded Oncodesign Société Anonyme, serves as its Chairman of the Board and has been its Chief Executive Officer since May 18, 2010.

CEO Compensation
  • Insufficient data for Philippe to compare compensation growth.
  • Philippe's remuneration is lower than average for companies of similar size in France.
Management Team Tenure

Average tenure and age of the Oncodesign Société Anonyme management team in years:

9
Average Tenure
57
Average Age
  • The average tenure for the Oncodesign Société Anonyme management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Philippe Genne

TITLE
Founder
COMPENSATION
€204K
TENURE
9 yrs

Arnaud Lafforgue

TITLE
Chief Financial & Administrative Officer
TENURE
1.1 yrs

Jan Hoflack

TITLE
Chief Scientific Officer
AGE
58

Catherine Genne

TITLE
Deputy Managing Director
COMPENSATION
€24K

Olivier Duchamp

TITLE
Member of Executive Board
TENURE
11.3 yrs

Francis Bichat

TITLE
Member of Executive Board
TENURE
11.3 yrs

Xavier Morge

TITLE
Head of Business Development & Marketing
TENURE
1.8 yrs

Thierry Billoué

TITLE
Head of Human Resources

Fabrice Viviani

TITLE
Head of the Experimentation Division
AGE
53

Alexis Denis

TITLE
Head of the Discovery Division
AGE
57
Board of Directors

Catherine Genne

TITLE
Deputy Managing Director
COMPENSATION
€24K

Kamel Besseghir

TITLE
Independent Director
COMPENSATION
€4K
TENURE
5.3 yrs

Philippe Genne

TITLE
Founder
COMPENSATION
€204K

Karine Lignel

TITLE
Director
AGE
48
TENURE
11 yrs

Ed Roberts

TITLE
Member of Scientific Advisory Board

Sergio Roman-Roman

TITLE
Member of Scientific Advisory Board

Michel Janicot

TITLE
Member of Scientific Advisory Board

Jean-Yves Bonnefoy

TITLE
Member of Scientific Advisory Board
AGE
58

Pierre Fumoleau

TITLE
Member of Scientific Advisory Board

Mats Bergström

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Oncodesign Société Anonyme's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Oncodesign Société Anonyme has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Does Oncodesign Société Anonyme's (EPA:ALONC) CEO Pay Compare Well With Peers?

Philippe Genne has been the CEO of Oncodesign Société Anonyme (EPA:ALONC) since 2010. … This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Philippe Genne's Compensation Compare With Similar Sized Companies?

Simply Wall St -

Is Oncodesign Société Anonyme's (EPA:ALONC) CEO Paid At A Competitive Rate?

First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Philippe Genne's Compensation Compare With Similar Sized Companies. … Our data indicates that Oncodesign Société Anonyme is worth €61m, and total annual CEO compensation is €204k.

Simply Wall St -

Is Oncodesign Société Anonyme's (EPA:ALONC) CEO Paid Enough Relative To Peers?

Philippe Genne took the helm as Oncodesign Société Anonyme's (EPA:ALONC) CEO and grew market cap to €65.97m recently. … This is because, if incentives are aligned, more value is created for shareholders which directly impacts your returns as an investor. … Check out our latest analysis for Oncodesign Société Anonyme

Simply Wall St -

Should You Sell Oncodesign Société Anonyme (EPA:ALONC) At This PE Ratio?

Formula Price-Earnings Ratio = Price per share ÷ Earnings per share P/E Calculation for ALONC Price per share = €9.82 Earnings per share = €0.076 ∴ Price-Earnings Ratio = €9.82 ÷ €0.076 = 128.4x On its own, the P/E ratio doesn’t tell you much; however, it becomes extremely useful when you compare it with other similar companies. … For example, if you accidentally compared lower growth firms with ALONC, then ALONC’s P/E would naturally be higher since investors would reward ALONC’s higher growth with a higher price. … Alternatively, if you inadvertently compared riskier firms with ALONC, ALONC’s P/E would again be higher since investors would reward ALONC’s lower risk with a higher price as well.

Simply Wall St -

Company Info

Description

Oncodesign Société Anonyme, a biotechnology company, conducts research and development work on new therapeutic and diagnostic tools along with pharmaceutical firms, biotech companies, public research institutions, and investment groups. It offers integrated drug discovery services; in vitro and in vivo pharmacology services for proof of concept stage; services for studying the metabolism and pharmacokinetics of drug candidates; and translational biomarkers, biodecontamination/biosafety, and biobanking services. The company is also involved in the analysis of new chemical and biological entities, and membrane proteins; and immune analysis and monitoring, and microbiological monitoring. In addition, it engages in the kinase inhibitor development programs, and licensing of Kinase inhibitors in oncology, and CNS and inflammation technologies. The company was founded in 1995 and is headquartered in Dijon, France.

Details
Name: Oncodesign Société Anonyme
ALONC
Exchange: ENXTPA
Founded: 1995
€50,463,902
6,801,065
Website: http://www.oncodesign.com
Address: Oncodesign Société Anonyme
20 rue Jean Mazen,
B.P. 27627,
Dijon,
Burgundy, 21076,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA ALONC Ordinary Shares Euronext Paris FR EUR 02. Apr 2014
Number of employees
Current staff
Staff numbers
229
Oncodesign Société Anonyme employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/21 22:14
End of day share price update: 2019/05/21 00:00
Last estimates confirmation: 2019/04/12
Last earnings filing: 2019/04/11
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.